134 related articles for article (PubMed ID: 37314131)
1. Effectiveness and safety of ustekinumab dose escalation in Crohn's disease: a multicenter observational study.
Olmedo Martín RV; Vázquez Morón JM; Martín Rodríguez MDM; Lázaro Sáez M; Hernández Martínez Á; Argüelles-Arias F
Rev Esp Enferm Dig; 2023 Dec; 115(12):686-692. PubMed ID: 37314131
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
Kopylov U; Hanzel J; Liefferinckx C; De Marco D; Imperatore N; Plevris N; Baston-Rey I; Harris RJ; Truyens M; Domislovic V; Vavricka S; Biemans V; Myers S; Sebastian S; Ben-Horin S; González Lama Y; Gilletta C; Ariella BS; Zelinkova Z; Weisshof R; Storan D; Zittan E; Farkas K; Molnar T; Franchimont D; Cremer A; Afif W; Castiglione F; Lees C; Barreiro-de Acosta M; Lobaton T; Doherty G; Krznaric Z; Pierik M; Hoentjen F; Drobne D
Aliment Pharmacol Ther; 2020 Jul; 52(1):135-142. PubMed ID: 32412134
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
Chaparro M; Baston-Rey I; Fernández-Salgado E; González García J; Ramos L; Diz-Lois Palomares MT; Argüelles-Arias F; Iglesias Flores E; Cabello M; Rubio Iturria S; Núñez Ortiz A; Charro M; Ginard D; Dueñas Sadornil C; Merino Ochoa O; Busquets D; Iyo E; Gutiérrez Casbas A; Ramírez de la Piscina P; Boscá-Watts MM; Arroyo M; García MJ; Hinojosa E; Gordillo J; Martínez Montiel P; Velayos Jiménez B; Quílez Ivorra C; Vázquez Morón JM; María Huguet J; González-Lama Y; Muñagorri Santos AI; Amo VM; Martín-Arranz MD; Bermejo F; Martínez Cadilla J; Rubín de Célix C; Fradejas Salazar P; San Román AL; Jiménez N; García López S; Figuerola A; Jiménez I; Martínez Cerezo FJ; Taxonera C; Varela P; de Francisco R; Monfort D; Molina Arriero G; Hernández Camba A; García-Alonso FJ; Van Domselaar M; Pajares Villarroya R; Núñez A; Rodríguez Moranta F; Marín-Jiménez I; Robles Alonso V; Martín Rodríguez MDM; Camo-Monterde P; García Tercero I; Navarro Llavat M; Arias García L; Hervías Cruz D; Sulleiro S; Novella C; Vispo E; Barreiro-de Acosta M; Gisbert JP
Inflamm Bowel Dis; 2022 Nov; 28(11):1725-1736. PubMed ID: 35166347
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study.
Fumery M; Peyrin-Biroulet L; Nancey S; Altwegg R; Gilletta C; Veyrard P; Bouguen G; Viennot S; Poullenot F; Filippi J; Buisson A; Bozon A; Brazier F; Pouillon L; Flourie B; Boivineau L; Siproudhis L; Laharie D; Roblin X; Diouf M; Treton X
J Crohns Colitis; 2020 Sep; ():. PubMed ID: 32898232
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification.
Dalal RS; Njie C; Marcus J; Gupta S; Allegretti JR
Inflamm Bowel Dis; 2021 Jul; 27(8):1294-1301. PubMed ID: 33146703
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis.
Meserve J; Ma C; Dulai PS; Jairath V; Singh S
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2728-2740.e1. PubMed ID: 34628078
[TBL] [Abstract][Full Text] [Related]
8. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
Inflamm Bowel Dis; 2017 May; 23(5):833-839. PubMed ID: 28328624
[TBL] [Abstract][Full Text] [Related]
9. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
Ollech JE; Normatov I; Peleg N; Wang J; Patel SA; Rai V; Yi Y; Singer J; Dalal SR; Sakuraba A; Cohen RD; Rubin DT; Pekow J
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):104-110. PubMed ID: 32109634
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort.
Casas Deza D; García López S; Lafuente Blasco M; Vicente Lidón R; Nerín de la Puerta J; Peña Gonzalez E; Ber Nieto Y; Charro Calvillo M; Alcalá Escriche MJ; Gomollón García F; Arroyo Villarino M
Gastroenterol Hepatol; 2020 Mar; 43(3):126-132. PubMed ID: 31866167
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study.
Thomas PWA; van Caem M; West RL; Russel MGVM; Jansen JM; Römkens TEH; Hoentjen F;
Eur J Gastroenterol Hepatol; 2023 Mar; 35(3):261-269. PubMed ID: 36708296
[TBL] [Abstract][Full Text] [Related]
13. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Bermejo F; Jiménez L; Algaba A; Vela M; Bastida G; Merino O; López-García A; Melcarne L; Rodríguez-Lago I; de la Maza S; Bouhmidi A; Barreiro-de Acosta M; López-Serrano P; Carrillo-Palau M; Mesonero F; Orts B; Bonillo D; Granja A; Guerra I
Inflamm Bowel Dis; 2022 Jan; 28(1):41-47. PubMed ID: 33528018
[TBL] [Abstract][Full Text] [Related]
14. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
Fumery M; Defrance A; Roblin X; Altwegg R; Caron B; Hébuterne X; Stefanescu C; Meyer A; Nachury M; Laharie D; Nancey S; Le Berre C; Serrero M; Geyl S; Giletta C; Ah-Soune P; Duveau N; Uzzan M; Abitbol V; Biron A; Tran-Minh ML; Paupard T; Vuitton L; Elgharabawy Y; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2023 Feb; 57(4):426-434. PubMed ID: 36534763
[TBL] [Abstract][Full Text] [Related]
16. Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.
Hanžel J; Koželj M; Špes Hlastec A; Kurent T; Sever N; Zdovc J; Smrekar N; Novak G; Štabuc B; Grabnar I; Drobne D
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e831-e836. PubMed ID: 34402470
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
20. Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease.
Forss A; Clements M; Myrelid P; Strid H; Söderman C; Wagner A; Andersson D; Hjelm F; ; Olén O; Halfvarson J; Ludvigsson JF
Dig Dis Sci; 2023 Jan; 68(1):65-76. PubMed ID: 35459973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
